Cargando…

Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis

BACKGROUND: Pulmonary arterial hypertension (PAH) is a fatal disease characterized by pulmonary vascular remodeling and increased pulmonary artery pressure, leading to impaired lung oxygenation, right heart failure, and even death. Although great advances have been made in PAH-targeted medications f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Fen, Wu, Kun, Zhu, Yong-zhi, Jiang, Jun-jun, Zhang, Gui, Liu, Jun, Xiao, Ping, Tian, Yang, Zhang, Wei, Zhang, Sheng, Hou, Feng, Bao, Zhong-wu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875131/ https://www.ncbi.nlm.nih.gov/pubmed/36712266 http://dx.doi.org/10.3389/fcvm.2022.1055897

Ejemplares similares

Lipocalin-Like Prostaglandin D Synthase but Not Hemopoietic Prostaglandin D Synthase Deletion Causes Hypertension and Accelerates Thrombogenesis in Mice
por: Song, Wen-Liang, et al.
Publicado: (2018)

Endothelin and Endothelin Antagonists in Chronic Kidney Disease
por: Kohan, Donald E., et al.
Publicado: (2014)

Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors
por: Frantz, Robert P., et al.
Publicado: (2020)

Effect of perindopril on pulse-wave velocity and endothelin-1 in black hypertensive patients
por: Osuch, Elzbieta, et al.
Publicado: (2012)

The safety of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension: Protocol for a systemic review and network meta-analysis
por: Gu, Zhi-Chun, et al.
Publicado: (2018)

Endothelin Receptors and Their Antagonists()()
por: Maguire, Janet J., et al.
Publicado: (2015)

Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension
por: Droste, Annette S, et al.
Publicado: (2009)

Plasma Big Endothelin-1 Levels and Long-Term Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention
por: Lyu, Si-qi, et al.
Publicado: (2022)

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension
por: Steiner, M Kathryn, et al.
Publicado: (2008)

Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review
por: Zhang, Li, et al.
Publicado: (2020)

Andrographolide Promotes Interaction Between Endothelin-Dependent EDNRA/EDNRB and Myocardin-SRF to Regulate Pathological Vascular Remodeling
por: Hu, Wangming, et al.
Publicado: (2022)

The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and Sepsis
por: Kowalczyk, Agata, et al.
Publicado: (2014)

Long-Term Effect of a Vaccine Targeting Endothelin-1 Receptor Type A in Pulmonary Arterial Hypertension
por: Dai, Yong, et al.
Publicado: (2021)

Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?
por: Badagliacca, Roberto, et al.
Publicado: (2020)

Paradoxical effects of streptozotocin-induced diabetes on endothelial dysfunction in stroke-prone spontaneously hypertensive rats
por: Zhong, Mei-Fang, et al.
Publicado: (2011)

Endothelin Receptor Antagonists in Kidney Disease
por: Martínez-Díaz, Irene, et al.
Publicado: (2023)

Overactive Bladder Syndrome and the Potential Role of Prostaglandins and Phosphodiesterases: An Introduction
por: Rahnama'i, Mohammad Sajjad, et al.
Publicado: (2013)

Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition
por: Cavasin, Maria A, et al.
Publicado: (2014)

Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients
por: Lan, Wei-Fang, et al.
Publicado: (2022)

VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension
por: Hamidi, Sayyed A, et al.
Publicado: (2011)

Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
por: Correale, Michele, et al.
Publicado: (2018)

Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
por: Tynan, Timothy, et al.
Publicado: (2019)

Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension
por: Verweij, Pierre, et al.
Publicado: (2020)

Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
por: Angeli, Fabio, et al.
Publicado: (2021)

Elevated Plasma Big Endothelin-1 at Admission Is Associated With Poor Short-Term Outcomes in Patients With Acute Decompensated Heart Failure
por: Mo, Ran, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat
por: Geng, Chang, et al.
Publicado: (2023)

Rationale for the Use of Prostaglandins and Phosphodiesterase Inhibitors in the Treatment of Functional Bladder Disorders
por: Rahnama'i, Mohammad Sajjad, et al.
Publicado: (2013)

Functional Interaction of Endothelin Receptors in Mediating Natriuresis Evoked by G Protein–Coupled Estrogen Receptor 1
por: Gohar, Eman Y., et al.
Publicado: (2021)

Antidiuretic Effects of the Endothelin Receptor Antagonist Avosentan
por: Baltatu, Ovidiu Constantin, et al.
Publicado: (2012)

Iontophoresis of Endothelin Receptor Antagonists in Rats and Men
por: Roustit, Matthieu, et al.
Publicado: (2012)

Endothelin antagonists in subarachnoid hemorrhage: what next?
por: Macdonald, R Loch
Publicado: (2012)

Evidence for biased agonists and antagonists at the endothelin receptors
por: Maguire, Janet J.
Publicado: (2016)

Body mass index, neck circumference, and hypertension: a prospective cohort study
por: Ren, Tao-jun, et al.
Publicado: (2023)

Pipersentan: A De Novo Synthetic Endothelin Receptor Antagonist that Inhibits Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension
por: Zhang, Zeyu, et al.
Publicado: (2022)

Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
por: Belge, Catharina, et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!
por: Maiolino, Giuseppe, et al.
Publicado: (2015)

Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH
por: Wang, Xing-Huan, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting
por: Wu, Yue, et al.
Publicado: (2021)

Endothelin antagonists: new bullets against lung injury?
por: Leeman, Marc
Publicado: (2005)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v7hskn3phpeqmvtifnak3kikqt